Home/Specialties/Oncology
Revenue management for oncologyYou Bought the Drug Before You Billed It. What Happens If It Is Denied?
Oncology inverts the usual economics of a medical practice. Everywhere else, an unpaid claim is revenue that did not arrive. Here the practice has already purchased the drug, already paid for it, and already given it to the patient. A denied or underpaid drug claim is not forgone income. It is a loss that has already happened, and the margin it has to be absorbed out of is set by a formula the practice does not influence.
Start with the free CareVixis practice assessment. No email required.
You Pay for the Drug First.
It is purchased, stocked and administered before any claim exists.
That is the ordinary way oncology works, and it changes everything downstream.
So a Denial Is Already a Loss.
Not revenue that has not arrived. Money that has left, against product already given.
Being patient with that balance costs more than being patient usually does.
And the Margin Is Set Elsewhere.
Payment is capped by a formula built from manufacturers' reported prices and the labelled vial amount.
Nothing your practice does changes the limit.
Which Makes Small Shortfalls Serious.
A claim paid slightly under still paid, so nothing flags it.
In this specialty that shortfall lands straight against what you paid for the drug.
That Is the Work.
CareVixis manages authorisations, denials, appeals and underpayment detection around your existing systems.
Nothing clinical changes.
In oncology, accounts receivable is not revenue waiting. It is capital out of the door.
The detail, if you want it
What the regulation says about the drug payment basis and the labelled vial amount, why a denial here behaves differently, where oncology practices lose money, and the questions worth asking about your own revenue.
How does Medicare pay for drugs given in the office?
At the lesser of the actual charge on the claim or a limit calculated from the average sales price. The limit is built from manufacturers' reported prices rather than from what a particular practice paid, so a practice that buys badly, or buys at a bad moment, absorbs the difference.
The calculation is tied to the label. CMS calculates the payment limit “based on the amount of product included in a vial or other container as reflected on the FDA-approved label”, additional product in the container “does not represent a cost to providers and is not incorporated into the ASP payment limit”, and “no payment is made for amounts of product in excess of that reflected on the FDA-approved label”.
What the Regulation Actually Says
["Quotations from 42 CFR Part 414, cited below. This is the payment basis that decides whether a practice's drug spend comes back.", 'The important thing about the formula is that it is external. Nothing a practice does to its own purchasing changes the limit; purchasing only changes which side of it the practice lands on.']
| Where it bites | What the published rule says |
|---|---|
| The payment basis | Payment is the lesser of the actual charge on the claim for program benefits, or a limit calculated as a set proportion of the average sales price, subject to stated limitations and exceptions. |
| What the limit is built on | “CMS calculates an average sales price payment limit based on the amount of product included in a vial or other container as reflected on the FDA-approved label.” |
| Overfill | “Additional product contained in the vial or other container does not represent a cost to providers and is not incorporated into the ASP payment limit.” |
| The hard limit | “No payment is made for amounts of product in excess of that reflected on the FDA-approved label.” |
| Multiple source drugs | For products within the same multiple source drug billing and payment code, the average sales price is “the volume-weighted average of the manufacturers’ average sales prices for those drug products”. |
| Where the price comes from | The limit is derived from manufacturers’ reported average sales prices rather than from the acquisition cost of any individual practice. |
CareVixis states the regulation as it is written. The proportion used in the formula, the quarterly pricing files and the applicable limitations and exceptions are published by CMS and revised; they are not restated here.
A Denial Here Is Not a Missed Opportunity. It Is a Cheque Already Written.
The ordinary mental model for accounts receivable is that unpaid claims are money waiting. In a buy-and-bill practice a meaningful share of the balance is money already spent, on product that is already in a patient, and it does not come back by being patient about it.
That changes what good revenue cycle management looks like here. Speed matters more, because the working capital is already out of the door. Authorisation matters more, because an authorisation obtained after administration is worth much less than one obtained before. And underpayment detection matters more than in almost any other specialty, because the margin between the payment limit and the acquisition cost is thin enough that a small shortfall can turn a treatment negative.
None of that is visible from a denial rate. A practice can have very few denials and still be losing money on drugs, because the losses arrive as adjustments, as units not paid, and as authorisations that did not cover what was given.
What an unpaid claim usually means
- Revenue that has not arrived yet.
- Time to work the appeal.
- A balance that can age.
- An opportunity cost.
What it means here
- Money already spent on product.
- Working capital already committed.
- A loss that is realised, not pending.
- A margin that cannot absorb much.
Where an Oncology Practice Loses Money
Not every practice sees all of these. They are what CareVixis expects to look at first on an oncology account.
Units billed against the label
Payment is calculated on the amount reflected on the approved label, and no payment is made for amounts in excess of it. Unit conversion errors here are expensive in both directions.
Wastage handled inconsistently
How discarded product is documented and reported is a defined process rather than a matter of local habit, and inconsistency across a practice is visible to a reviewer.
Authorisation after administration
An authorisation obtained afterwards is worth far less than one obtained before, and in a buy-and-bill setting the product is already gone.
Regimen changes not reauthorised
A change of agent, dose or schedule can fall outside what was approved. The clinical decision is right; the authorisation no longer matches it.
Underpayment against a thin margin
A claim paid below the expected limit still pays, so it appears on no denial report, and the shortfall lands directly against acquisition cost.
Administration codes adrift from the drug
The administration service and the product are billed together and reviewed together. Where one is right and the other is not, both are questioned.
CareVixis publishes no denial rate, recovery rate or resolution time for oncology or any other specialty, and does not suggest any practice experiences all of this. What is happening in a particular practice is a question for its own data.
Where This Fits Around What You Already Run
Where oncology drug revenue is decided, and where CareVixis joins it. Note how much of it happens before the claim.
- Regimen decidedThe clinical decision, which sets what will be purchased and what must be authorised.
- AuthorisationObtained before administration wherever possible, and matched to the agent, dose and schedule actually planned.
- Purchase and administrationThe practice's money leaves here. Everything after this point is recovery rather than earning.
- Claim, in units against the labelThe product and the administration service, billed to match what was given and what was discarded.
- VixisIQ™CareVixis revenue intelligence reads the resulting remittance information, where appropriate data can be obtained and normalized, and compares what was paid against what the payment basis predicts.
- VixisTrace™Where a claim was denied, rejected or underpaid, CareVixis claim root cause analysis works eight stages: Detect, Investigate, Identify, Correct, Prevent, Resubmit, Verify, Monitor.
- The CareVixis teamPeople chase the authorisation, the appeal and the shortfall that no report flagged. Denials are worked the day they arrive; submitting the corrected claim or appeal the same day is the CareVixis standard.
Questions Worth Asking About Your Own Revenue
Put these to CareVixis too. In a buy-and-bill practice, speed and detection matter more than they do anywhere else.
-
How quickly is a drug denial worked?
Ask for the interval in days. The money is already spent, so time is not neutral here.
-
How would a shortfall against the payment limit be noticed?
The claim paid, so nothing flagged it. Ask what compares payment against the expected amount, per unit.
-
What share of administrations are authorised in advance?
Ask for the number rather than the intention.
-
What happens when a regimen changes?
Ask who re-checks the authorisation against the new agent, dose or schedule.
-
How is discarded product documented?
Ask to see the process written down, and ask whether every site follows the same one.
-
Do units reconcile to the label?
Ask who checks unit conversions, because errors here are systematic rather than occasional.
-
Are administration codes reviewed with the drug?
Ask whether they are checked together, since they are reviewed together.
-
What is our days in accounts receivable for drug claims specifically?
Ask for it separately from the rest. Blended figures hide this.
-
Where are the people working our claims?
Ask whether you can speak to them directly. CareVixis is 100% US based and does not outsource.
Using Oncology? Keep It.
Keep the oncology information system and the pharmacy workflow you already run. CareVixis manages the revenue cycle around them and does not require a software change to begin.
Keeping your system is a supported outcome, not a fallback. If a practice later wants to move to the CareVixis platform, that move may be offered at no additional migration charge, and everything the patient sees still carries the practice's own name and branding.
Keep your systems. Get the money back faster than you spent it.
Questions Oncology Practices Ask
What is the payment basis for office-administered drugs?
The lesser of the actual charge on the claim or a payment limit calculated from the average sales price, subject to the applicable limitations and exceptions in the regulation. The limit derives from manufacturers' reported prices rather than from an individual practice's acquisition cost.
How does the vial size affect payment?
CMS calculates the payment limit based on the amount of product included in a vial or other container as reflected on the FDA-approved label. Additional product in the container is not treated as a cost to providers and is not incorporated into the limit, and no payment is made for amounts in excess of the labelled amount.
Why is a drug denial worse than an ordinary denial?
Because the practice has already purchased the product and administered it. The unpaid claim is not revenue waiting to arrive; it is money already spent, against a margin set externally.
How are multiple source drugs priced?
For products within the same multiple source drug billing and payment code, the average sales price is the volume-weighted average of the manufacturers' average sales prices for those products.
Can CareVixis detect underpayments on drug claims?
That is one of the first things it looks at in this specialty. A claim paid below the expected limit still pays, so it appears on no denial report, and in oncology the shortfall lands directly against acquisition cost.
What is VixisIQ™?
VixisIQ™ is the CareVixis revenue intelligence technology. It analyses revenue cycle and remittance data to surface payment patterns, adjustments, denial and rejection patterns, payer behaviour and accounts receivable trends. What it can analyse for a particular practice depends on the data that practice is able to make available.
What is VixisTrace™?
VixisTrace™ is the CareVixis claim root cause analysis technology, covering rejected, denied, underpaid and otherwise problematic claims across eight stages. The objective is continuous improvement: identify preventable patterns, address their causes, and reduce unnecessary repeat failures.
Can CareVixis work aged oncology balances?
Yes, as a separate arrangement charged on what is actually recovered rather than on the balance handed over. Terms are on the pricing page.
Keep Oncology. Add Revenue Intelligence.
Everywhere else, working accounts receivable recovers revenue. Here it recovers capital, and the difference is why speed is worth paying for.
Free. No obligation. No email required.
Sources
- Electronic Code of Federal Regulations, 42 CFR § 414.904 Average sales price as the basis for payment. Source of the statement that payment is the lesser of the actual charge on the claim for program benefits or a limit based on the average sales price subject to stated limitations and exceptions, that CMS calculates the payment limit based on the amount of product included in a vial or other container as reflected on the FDA-approved label, that additional product in the container does not represent a cost to providers and is not incorporated into the limit, and that no payment is made for amounts of product in excess of that reflected on the label. ecfr.gov. Accessed 21 September 2026.
- Electronic Code of Federal Regulations, 42 CFR § 414.904, multiple source drugs. Source of the statement that the average sales price for all drug products included within the same multiple source drug billing and payment code is the volume-weighted average of the manufacturers' average sales prices for those drug products. ecfr.gov. Accessed 21 September 2026.
- Electronic Code of Federal Regulations, 42 CFR § 410.26 Services and supplies incident to a physician's professional services: Conditions. Cited because drug administration in an office setting is furnished by auxiliary personnel under the incident-to conditions, which require a noninstitutional setting, an integral though incidental relationship to the physician's service, and generally direct supervision. ecfr.gov. Accessed 21 September 2026.
These regulations are amended from time to time and the eCFR pages cited carry the current text. Quarterly pricing files and the applicable payment proportion are published separately by CMS.
The CareVixis Model, Applied to Medical Billing for Oncology Practices
The six CareVixis pillars stay consistent (Revenue Cycle, Credentialing, Technology, Communications, Operations and Growth) while the workflow adapts to this specialty's documentation, coding, payer and operational requirements. Keep the systems that work for you; CareVixis connects responsibility around them.